News

Innovative Vaccine Development Partnership Between LenioBio and ReciBioPharm

Innovative Vaccine Development Partnership Between LenioBio and ReciBioPharm

Collaboration for Accelerated Vaccine Development

Advancing CEPI's 100 Days Mission to Accelerate Vaccine Development

LenioBio, a trailblazer in rapid cell-free protein expression technologies, has embarked on a significant collaboration with ReciBioPharm. This partnership aims to enhance protein manufacturing capabilities and expedite vaccine production, a vital step in addressing global health challenges.

Expanding on Success

The collaboration is part of a broader expansion of LenioBio's initiatives, which received funding from CEPI (Coalition for Epidemic Preparedness Innovations). Their project highlights the speed and capacity of LenioBio's proprietary ALiCE® technology, specifically designed for producing vaccine-related proteins for clinical trials. The project's initial stages brought notable achievements, with LenioBio successfully demonstrating the technology's reliable protein production capabilities utilizing cell-free DNA formats.

Quality and Safety Assurance

As part of their commitment to excellence, LenioBio also developed innovative quality control assays to ensure product integrity and safety during the entire protein production process. These advancements are crucial as they lay the groundwork for ensuring high standards in vaccine development.

Leveraging ReciBioPharm's Expertise

Through this collaboration, LenioBio will leverage ReciBioPharm's extensive expertise in the development and manufacture of complex biologics. This strategic alliance aims to optimize the production of vaccine proteins at an increased scale using ALiCE®. The partnership is set to cultivate groundbreaking advancements in vaccine manufacturing, ultimately leading to more efficient processes.

Meeting Urgent Health Needs

André Goerke, CEO of LenioBio, emphasized the significance of collaborating with ReciBioPharm, stating, "This alliance takes us closer to realizing the goal of swift vaccine development, crucial in addressing emerging health threats." Transferring production capabilities to a leading contract development and manufacturing organization (CDMO) enables the team to respond to urgent medical needs effectively.

Technology Transfer and Growth

The collaboration will also facilitate technology transfer aimed at 10-liter scale protein production. This will support pre-clinical studies, marking a critical milestone in establishing ALiCE® technology in a large-scale manufacturing environment. Additionally, it sets the stage for future Good Manufacturing Practice (GMP) applications, ensuring vaccines and therapeutics move effectively through clinical trials.

A Vision for Rapid Development

Vikas Gupta, president of ReciBioPharm, remarked on the importance of this collaboration in advancing recombinant protein manufacturing. He noted that the innovative ALiCE® technology has the potential to significantly impact global health by accelerating the development of vital vaccines and biologics. The partnership aligns with ReciBioPharm's commitment to fostering innovation and expediting solutions for emerging health threats.

Evaluating Protein Quality

Looking to the future, LenioBio plans to conduct comprehensive evaluations of the quality of proteins produced using ALiCE® technology. This includes in vivo studies that focus on dosage and efficacy. Regulatory discussions will also be pivotal as the company positions ALiCE® as a transformative platform for rapidly developing protein medicines and decreasing the timeline for vaccines to reach clinical trials.

The 100 Days Mission Explained

The 100 Days Mission, led by CEPI and backed by global leaders, aims to drastically decrease the vaccine development timeline. The initiative demonstrated its effectiveness by shortening the development period for the initial licensed COVID-19 vaccines significantly. This mission holds the promise of preventing future outbreaks from transforming into global health crises.

About LenioBio

LenioBio is at the forefront of biotechnology, pioneering a revolutionary protein expression platform. With its ALiCE® technology, LenioBio enables researchers and biopharmaceutical manufacturers to streamline their protein discovery and production processes, enhancing the efficiency with which drugs are brought to patients in need.

About ReciBioPharm

ReciBioPharm, a division of Recipharm, specializes in contract development and manufacturing for advanced therapy medicinal products (ATMPs). Their CDMO capabilities span from pre-clinical stages to commercial development, encompassing modern biological modalities such as live viruses and viral vectors. With a team of seasoned experts, ReciBioPharm is dedicated to supporting the advancement of innovative therapies crucial for patient care worldwide.

Frequently Asked Questions

What is the main goal of the collaboration between LenioBio and ReciBioPharm?

The collaboration aims to enhance protein manufacturing capabilities and expedite the production of vaccines.

How does the ALiCE® technology contribute to vaccine development?

ALiCE® technology allows for the rapid production of vaccine-relevant proteins, facilitating quicker clinical trial processes.

What is the significance of the 100 Days Mission?

The 100 Days Mission seeks to significantly shorten the time required to develop vaccines, aiming to prevent future pandemics.

Who are the key players in the collaboration?

LenioBio and ReciBioPharm are the primary organizations involved, with LenioBio pioneering protein expression technology and ReciBioPharm providing manufacturing expertise.

What steps will be taken to ensure the quality of produced proteins?

LenioBio will conduct in vivo studies and regulatory discussions to ensure the efficacy and safety of proteins produced using ALiCE® technology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 90

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 106

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 9

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 76

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 189

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 133

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from BioRestorative's CEO on Regenerative Medicine

Updated Category News Views 168

CEO Lance Alstodt Discusses BioRestorative's Vision In a recent interview on “The Big Biz Show,” the dynamic CEO of BioRestorative Therapies, Inc., Lance Alstodt, shared invaluable insights into the company's journey. As a pioneer in regenerative medicine, BioRestorative focuses on innovative stem cell-based therapies aimed at addressing various medical challenges....

Continue Reading
Hargreave Hale AIM VCT PLC NAV Announcement

Updated Category News Views 73

Hargreave Hale AIM VCT PLC (the “Company”) Net Asset Value Announcement As of the close of business on 16 August 2024, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc stands at: NAV per Ordinary share of 1p – 42.03 pence. Contact Information If you need more information, please reach out to: JTC (UK) Limited Uloma Adighibe Alexandria Tivey Email...

Continue Reading
Discover Luxury Living at Toll Brothers' New Community in Texas

Updated Category News Views 150

Introducing Toll Brothers at George's Ranch In a splendid showcase of luxury living, Toll Brothers, Inc. (NYSE:TOL) has unveiled its newest community, Toll Brothers at George's Ranch, located in the serene surroundings of Boerne, Texas. This exciting development marks an important addition to the San Antonio area, where elegance meets modern design. Grand Opening...

Continue Reading
xLean's TR1 Robot Revolutionizes Cleaning Technology

Updated Category News Views 224

xLean's Innovative TR1 Takes Center Stage xLean Robotics concluded an exciting showcase at IFA 2025, where its groundbreaking TR1, the world's first dual-form transformable floor washing robot, earned several prestigious awards. This innovative device was recognized as the 'Best in IFA Next Winner' and 'Best in Design Honoree,' and it was featured as one of the 'Top 5...

Continue Reading
Alpha Modus Sues H&M for Patent Infringement Regarding AI Tech

Updated Category News Views 165

Alpha Modus Files Patent Infringement Lawsuit Against H&M Alpha Modus, Corp. is making headlines for filing a substantial patent infringement lawsuit against H&M Fashion USA, Inc. in the United States District Court for the Eastern District of Texas, Marshall Division. This legal action centers around allegations that H&M's retail operations in the U.S. are infringing...

Continue Reading